AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Orthocell Marks US Milestone with First Surgery Using Remplir™ Nerve Repair Device
June 27, 2025 11:20 AM AEST| By Team Kalkine MediaHighlights,Orthocell,completes first US-based,Remplir,™ nerve repair surgery,Expanding US distributor network aids commercial rollout,Positioned for strong sales momentum through FY26,Orthocell Ltd (ASX:OCC) has reached a significant milestone in its...
CSL Shares in Focus: Is This ASX200 Healthcare Giant Still a Resilient Contender?
June 27, 2025 10:37 AM AEST| By Team Kalkine MediaHighlights,CSL (CSL) shares decline over 14% YTD in 2025,Healthcare sector shows resilience amid economic cycles,CSL’s business units continue to support long-term growth,CSL Limited (ASX:CSL), a key player in the Australian healthcare sector and a p...
Percheron Therapeutics (ASX:PER) Signs Global License Deal for HMBD-002, Eyes 2026 Trial Launch
June 26, 2025 02:08 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights to promising cancer immunotherapy asset.,Plans underway for Phase II trial of HMBD-002 by 2026.,Deal includes up to US$287M in milestones plus royalties.,Percheron Therapeutics (ASX:PER) has taken a strategi...
Percheron Therapeutics Strikes Global Deal for Promising Cancer Drug
June 26, 2025 01:26 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights for mid-stage cancer therapy HMBD-002,Clinical trials planned for 2026 with advanced immuno-oncology focus,Strategic pivot follows extensive search after prior asset setback,In a major development that marks...
Percheron’s Strategic Leap into Immuno-Oncology with VISTA Therapy Acquisition
June 26, 2025 01:16 PM AEST| By Team Kalkine MediaHighlights,Percheron secures global rights to develop cancer immunotherapy HMBD-002,The licensed drug targets VISTA, a novel checkpoint with promising potential,Phase II trials expected to commence in 2026 following successful Phase I,Melbourne-based...
Can ResMed (ASX:RMD) Shine in the ASX200 in 2025?
June 26, 2025 11:24 AM AEST| By Team Kalkine MediaHighlights,ResMed (RMD) shows solid financial growth with strong revenue and profit metrics,Valuation metrics indicate RMD shares are trading below historical averages,Net cash position and healthy returns reinforce the company's stability,ResMed (AS...
COH Shares: A Closer Look at This ASX200 Healthcare Leader
June 26, 2025 10:26 AM AEST| By Team Kalkine MediaHighlights,COH designs innovative hearing implants globally,Healthcare stocks offer resilient, sticky revenue,Valuation suggests COH trading below 5-year average,Cochlear Ltd (ASX:COH) has seen a slight uplift of 0.3% in its share price since the beg...
Singular Health Group Expands Market Footprint with New ASX Securities Listing
June 26, 2025 10:20 AM AEST| By Team Kalkine MediaHighlights,Singular Health Group adds 1.57 million new securities to ASX,Move supports strategic capital flexibility and expansion goals,Focus,remains,on digital innovation in medical imaging,Singular Health Group Ltd (ASX:SHG), a digital healthcare...
Why Sonic Healthcare (ASX:SHL) Is Still in the Spotlight on the ASX300
June 25, 2025 10:46 AM AEST| By Team Kalkine MediaHighlights,SHL shares reflect solid healthcare fundamentals,Sector supported by resilient demand trends,Valuation appears below historical average,The share price of Sonic Healthcare Ltd (ASX:SHL) has seen a modest decline of 4.2% since the beginning...
Biotron (ASX:BIT) Advances Hepatitis B Therapy with Positive Safety Milestone
June 24, 2025 04:07 PM AEST| By Team Kalkine MediaHighlights,Biotron completes initial safety trials for HBV therapy,Antiviral testing in preclinical models set to begin,Progress backed by recent funding round,Biotron (ASX:BIT), a clinical-stage biotechnology company, has achieved a significant mile...
Tryptamine Therapeutics Secures Ethics Approval for Psilocin BED Trial | ASX 200
June 23, 2025 02:43 PM AEST| By Team Kalkine MediaHighlights,Tryptamine Therapeutics gains approval to commence first-in-human trial for BED using TRP-8803,Study to assess safety and impact on BED and related psychiatric conditions,Patient recruitment underway with treatment scheduled to begin later...
Neurizon Therapeutics Unveils Promising Preclinical Findings for ALS Therapy
June 20, 2025 06:09 PM AEST| By Team Kalkine MediaHighlights,NUZ-001 shows promising blood-brain barrier penetration.,Strong preclinical evidence supports ALS treatment potential.,Reinforces Neurizon’s position in innovative neurological therapeutics.,Neurizon Therapeutics (ASX:NUZ) has taken a sign...
CSL Gains FDA Nod as ASX 200 Healthcare Faces Global Pressure
June 20, 2025 05:21 PM AEST| By Team Kalkine MediaHighlights,CSL Limited (ASX:CSL) receives FDA clearance for rare disease treatment,Healthcare stocks within the ASX 200 and ASX 100 indices reflect cautious sentiment,External trade and policy developments influence ASX 200 healthcare performance,CSL...
Orthocell’s Breakthrough in Nerve Repair Places It on the ASX200 Innovation Radar
June 20, 2025 03:40 PM AEST| By Team Kalkine MediaHighlights,Orthocell’s Remplir outperforms traditional suture-only nerve repair methods,Interim study results support rapid U.S. product rollout,Potential to impact ASX200 medical innovation landscape,Orthocell (ASX:OCC) has unveiled encouraging inte...
ECS Botanics (ASX:ECS) Faces Pressure Amid Revenue Concerns | All Ordinaries Spotlight
June 20, 2025 03:03 PM AEST| By Team Kalkine MediaHighlights,ECS Botanics Holdings Ltd shares decline amid shrinking revenue performance,Valuation metrics reflect subdued expectations compared to pharmaceutical peers,Broader All Ordinaries index maintains contrast with ECS’s sectoral challenges,ECS...
Arovella Therapeutics Extends Momentum on ASX 200 with Continued Growth Streak
June 20, 2025 02:46 PM AEST| By Team Kalkine MediaHighlights,Arovella Therapeutics continues gaining traction within the healthcare segment,Long-term revenue trend aligns with rising shareholder interest,Company performance draws attention across,ASX 200,and,All Ordinaries,indices,Arovella Therapeut...
Ramsay Health Care Faces Extended Downtrend | ASX 50 Healthcare Stock Performance Dips
June 20, 2025 02:40 PM AEST| By Team Kalkine MediaHighlights,Ramsay Health Care's earnings per share experienced extended contraction over recent years,Long-term share performance remained below broader market benchmarks,Dividends have offset some value loss, contributing to higher total shareholder...
Neurizon Therapeutics Unveils Promising Platform Therapy Potential for ALS and HD, Strengthening ASX200 Biotech Profile
June 20, 2025 11:50 AM AEST| By Team Kalkine MediaHighlights,NUZ-001 shows strong brain penetration in ALS and HD models,Promising neuroprotective effects,demonstrated,in multiple preclinical studies,Platform potential for broader neurodegenerative disorders,Neurizon Therapeutics (ASX:NUZ), a clinic...
Race Oncology (ASX:RAC) Launches First Patient Dosing in RC220 Trial
June 20, 2025 10:51 AM AEST| By Team Kalkine MediaHighlights,RC220 and doxorubicin combination enters Phase 1,No serious toxicities seen in,initial,patient,Expansion planned into Asia, US, and Europe,Race Oncology (ASX:RAC),has marked a pivotal moment in its drug development journey with the success...
Clarity Pharmaceuticals (ASX:CU6) Advances U.S. Manufacturing in ASX 300 Healthcare Sector
June 19, 2025 06:58 PM AEST| By Team Kalkine MediaHighlights,Clarity Pharmaceuticals (ASX:CU6) belongs to the ASX 300 and operates within the healthcare sector focused on radiopharmaceuticals,Recent manufacturing agreement with SpectronRX supports U.S. readiness for cancer imaging product developmen...
Advertise your brand on Kalkine Media